JP2015522658A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015522658A5 JP2015522658A5 JP2015524291A JP2015524291A JP2015522658A5 JP 2015522658 A5 JP2015522658 A5 JP 2015522658A5 JP 2015524291 A JP2015524291 A JP 2015524291A JP 2015524291 A JP2015524291 A JP 2015524291A JP 2015522658 A5 JP2015522658 A5 JP 2015522658A5
- Authority
- JP
- Japan
- Prior art keywords
- formulated
- pharmaceutical composition
- analgesics
- release
- use according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims 19
- 229940035676 analgesics Drugs 0.000 claims 18
- 239000000730 antalgic agent Substances 0.000 claims 18
- 229940123333 Phosphodiesterase 5 inhibitor Drugs 0.000 claims 11
- 239000002590 phosphodiesterase V inhibitor Substances 0.000 claims 11
- 238000013265 extended release Methods 0.000 claims 10
- 239000012729 immediate-release (IR) formulation Substances 0.000 claims 10
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 claims 8
- 230000003111 delayed effect Effects 0.000 claims 6
- 229960005489 paracetamol Drugs 0.000 claims 4
- IEHKWSGCTWLXFU-IIBYNOLFSA-N tadalafil Chemical compound C1=C2OCOC2=CC([C@@H]2C3=C([C]4C=CC=CC4=N3)C[C@H]3N2C(=O)CN(C3=O)C)=C1 IEHKWSGCTWLXFU-IIBYNOLFSA-N 0.000 claims 4
- 229960000835 tadalafil Drugs 0.000 claims 4
- 239000003795 chemical substances by application Substances 0.000 claims 3
- 230000027939 micturition Effects 0.000 claims 3
- 239000004480 active ingredient Substances 0.000 claims 2
- 230000002686 anti-diuretic effect Effects 0.000 claims 2
- 229940124538 antidiuretic agent Drugs 0.000 claims 2
- 239000000812 cholinergic antagonist Substances 0.000 claims 2
- CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 claims 2
- ZAFYATHCZYHLPB-UHFFFAOYSA-N zolpidem Chemical compound N1=C2C=CC(C)=CN2C(CC(=O)N(C)C)=C1C1=CC=C(C)C=C1 ZAFYATHCZYHLPB-UHFFFAOYSA-N 0.000 claims 2
- 229960001475 zolpidem Drugs 0.000 claims 2
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 claims 1
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 claims 1
- BLXXJMDCKKHMKV-UHFFFAOYSA-N Nabumetone Chemical compound C1=C(CCC(C)=O)C=CC2=CC(OC)=CC=C21 BLXXJMDCKKHMKV-UHFFFAOYSA-N 0.000 claims 1
- CMWTZPSULFXXJA-UHFFFAOYSA-N Naproxen Natural products C1=C(C(C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-UHFFFAOYSA-N 0.000 claims 1
- 229940099471 Phosphodiesterase inhibitor Drugs 0.000 claims 1
- 229960001138 acetylsalicylic acid Drugs 0.000 claims 1
- 230000000202 analgesic effect Effects 0.000 claims 1
- 230000001022 anti-muscarinic effect Effects 0.000 claims 1
- 230000002921 anti-spasmodic effect Effects 0.000 claims 1
- 239000003160 antidiuretic agent Substances 0.000 claims 1
- -1 antidiuretics Substances 0.000 claims 1
- 229940124575 antispasmodic agent Drugs 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 239000002702 enteric coating Substances 0.000 claims 1
- 238000009505 enteric coating Methods 0.000 claims 1
- 229960001680 ibuprofen Drugs 0.000 claims 1
- 229960000905 indomethacin Drugs 0.000 claims 1
- 239000003149 muscarinic antagonist Substances 0.000 claims 1
- 229960004270 nabumetone Drugs 0.000 claims 1
- 229960002009 naproxen Drugs 0.000 claims 1
- CMWTZPSULFXXJA-VIFPVBQESA-N naproxen Chemical compound C1=C([C@H](C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-VIFPVBQESA-N 0.000 claims 1
- 229960003940 naproxen sodium Drugs 0.000 claims 1
- CDBRNDSHEYLDJV-FVGYRXGTSA-M naproxen sodium Chemical compound [Na+].C1=C([C@H](C)C([O-])=O)C=CC2=CC(OC)=CC=C21 CDBRNDSHEYLDJV-FVGYRXGTSA-M 0.000 claims 1
- 239000002571 phosphodiesterase inhibitor Substances 0.000 claims 1
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US13/560,665 | 2012-07-27 | ||
| US13/560,665 US8445011B2 (en) | 2010-07-08 | 2012-07-27 | Delayed-release formulation for reducing the frequency of urination and method of use thereof |
| US13/800,761 | 2013-03-13 | ||
| US13/800,761 US20130196012A1 (en) | 2010-11-30 | 2013-03-13 | Extended-release formulation for reducing the frequency of urination and method of use thereof |
| US13/847,940 US8703184B2 (en) | 2010-07-08 | 2013-03-20 | Delayed-release formulation for reducing the frequency of urination and method of use thereof |
| US13/847,940 | 2013-03-20 | ||
| PCT/US2013/048616 WO2014018222A1 (en) | 2012-07-27 | 2013-06-28 | Pharmaceutical formulation for reducing frequency of urination and method of use thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017204851A Division JP2018039831A (ja) | 2012-07-27 | 2017-10-24 | 排尿頻度を減少させるための医薬製剤およびその使用の方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2015522658A JP2015522658A (ja) | 2015-08-06 |
| JP2015522658A5 true JP2015522658A5 (enExample) | 2016-07-28 |
Family
ID=49997724
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015524291A Pending JP2015522658A (ja) | 2012-07-27 | 2013-06-28 | 排尿頻度を減少させるための医薬製剤およびその使用の方法 |
| JP2015524292A Pending JP2015522659A (ja) | 2012-07-27 | 2013-06-28 | 夜尿症のための医薬製剤およびその使用の方法 |
| JP2017204851A Pending JP2018039831A (ja) | 2012-07-27 | 2017-10-24 | 排尿頻度を減少させるための医薬製剤およびその使用の方法 |
| JP2018078173A Pending JP2018127482A (ja) | 2012-07-27 | 2018-04-16 | 夜尿症のための医薬製剤およびその使用の方法 |
Family Applications After (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015524292A Pending JP2015522659A (ja) | 2012-07-27 | 2013-06-28 | 夜尿症のための医薬製剤およびその使用の方法 |
| JP2017204851A Pending JP2018039831A (ja) | 2012-07-27 | 2017-10-24 | 排尿頻度を減少させるための医薬製剤およびその使用の方法 |
| JP2018078173A Pending JP2018127482A (ja) | 2012-07-27 | 2018-04-16 | 夜尿症のための医薬製剤およびその使用の方法 |
Country Status (16)
| Country | Link |
|---|---|
| US (3) | US20160022615A1 (enExample) |
| EP (3) | EP2877179A4 (enExample) |
| JP (4) | JP2015522658A (enExample) |
| KR (2) | KR20150048741A (enExample) |
| CN (4) | CN104470522A (enExample) |
| AU (3) | AU2013293489B2 (enExample) |
| BR (2) | BR112014031306A2 (enExample) |
| CA (2) | CA2875818A1 (enExample) |
| HK (4) | HK1205932A1 (enExample) |
| IL (3) | IL236028A0 (enExample) |
| MX (2) | MX2015001188A (enExample) |
| MY (1) | MY171526A (enExample) |
| RU (3) | RU2019101864A (enExample) |
| SG (2) | SG11201500601QA (enExample) |
| WO (2) | WO2014018223A1 (enExample) |
| ZA (2) | ZA201408993B (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20180054655A (ko) * | 2015-09-01 | 2018-05-24 | 웰즐리 파마슈티컬스 엘엘씨 | 연장, 지연 및 즉시 방출 제형 제조 방법 및 용도 |
| KR20180066113A (ko) * | 2015-09-30 | 2018-06-18 | 웰즐리 파마슈티컬스 엘엘씨 | 배뇨 빈도 감소용 조성물, 제조 방법 및 용도 |
| CN108391420A (zh) * | 2015-09-30 | 2018-08-10 | 韦尔斯利医药有限公司 | 用于减少排尿频率的组合物及其制备方法和应用 |
| TW201726114A (zh) * | 2015-11-23 | 2017-08-01 | 魏斯理製藥公司 | 降低排尿頻率之組成物、其製備方法、及其應用 |
| AU2018365287A1 (en) * | 2017-11-07 | 2020-05-28 | Poviva Corp. | Food and beverage compositions comprising PDE5 inhibitors |
| KR20230152046A (ko) | 2021-02-23 | 2023-11-02 | 오츠카 세이야쿠 가부시키가이샤 | 센타나파딘 제약 제제, 및 그의 제조 및 사용 방법 |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2002533380A (ja) * | 1998-12-23 | 2002-10-08 | アルザ・コーポレーション | 多孔性粒子を含む剤形 |
| EP1214039A2 (en) * | 1999-09-09 | 2002-06-19 | Androsolutions, Inc. | Methods and compositions for preventing and treating urinary tract disorders |
| CN1471397A (zh) * | 2000-08-30 | 2004-01-28 | 利利艾科斯有限公司 | 治疗偏头痛的方法 |
| US20040259912A1 (en) * | 2001-09-28 | 2004-12-23 | Takahiro Matsumoto | Benzine derivatives, process for preparing the same and use thereof |
| AU2003211078A1 (en) * | 2002-02-19 | 2003-09-09 | Pharmacia Corporation | Use of cyclooxygenase inhibitors and antimuscarinic agents for the treatment of incontinence |
| AU2003291302A1 (en) * | 2002-11-06 | 2004-06-03 | Azaya Therapeutics, Inc. | Method for treatment of premature ejaculation in humans |
| CA2646729A1 (en) * | 2005-03-21 | 2006-09-28 | Dov Pharmaceutical, Inc. | Methods and compositions for the treatment of urinary incontinence |
| EP1741444A1 (en) * | 2005-07-05 | 2007-01-10 | Jerini AG | Kinin antagonists for treating bladder dysfunction |
| US20080166407A1 (en) * | 2005-07-29 | 2008-07-10 | Shalaby Shalaby W | Solid oral formulations for combination therapy |
| WO2007083323A2 (en) * | 2006-01-23 | 2007-07-26 | Panacea Biotec Limited. | Modified release oral dosage form comprising desmopressin |
| WO2007113243A2 (en) * | 2006-03-31 | 2007-10-11 | Investigación Y Clínica Andrológicas S.L. | Use of pde 5 inhibitors for the treatment of overactive bladder |
| KR20140143461A (ko) * | 2007-08-06 | 2014-12-16 | 알레간 인코포레이티드 | 데스모프레신 약물 전달을 위한 방법 및 장치 |
| CN101664555A (zh) * | 2008-09-02 | 2010-03-10 | 许洁 | 用于治疗泌尿生殖系统感染性疾病的联合药物组合物 |
| CN102028693A (zh) * | 2009-09-30 | 2011-04-27 | 梁超峰 | 含有5-型磷酸二酯酶抑制剂的直肠给药组合物 |
| US9260424B2 (en) * | 2009-10-26 | 2016-02-16 | Auspex Pharmaceuticals, Inc. | 4,6-diaminopyrimidine stimulators of soluble guanylate cyclase |
| US20120135050A1 (en) * | 2010-07-08 | 2012-05-31 | Wellesley Pharmaceuticals, Llc | Extended-release formulation for reducing the frequency of urination and method of use thereof |
| US20120010294A1 (en) * | 2010-07-08 | 2012-01-12 | Dill David A | Compositions and methods for the inhibition of muscle contraction |
| US8236857B2 (en) * | 2010-07-08 | 2012-08-07 | Wellesley Pharmaceuticals, Llc | Extended-release formulation for reducing the frequency of urination and method of use thereof |
| US20120244221A1 (en) * | 2010-07-08 | 2012-09-27 | Wellesley Pharmaceuticals, Llc | Extended-release formulation for reducing the frequency of urination and method of use thereof |
| US8236856B2 (en) * | 2010-07-08 | 2012-08-07 | Wellesley Pharmaceuticals, Llc | Delayed release formulation for reducing the frequency of urination and method of use thereof |
| US20120141554A1 (en) * | 2010-07-08 | 2012-06-07 | Wellesley Pharmaceuticals, Llc | Delayed release formulation for reducing the frequency of urination and method of use thereof |
-
2013
- 2013-06-28 CA CA2875818A patent/CA2875818A1/en not_active Abandoned
- 2013-06-28 CN CN201380038506.5A patent/CN104470522A/zh active Pending
- 2013-06-28 BR BR112014031306A patent/BR112014031306A2/pt not_active Application Discontinuation
- 2013-06-28 MX MX2015001188A patent/MX2015001188A/es unknown
- 2013-06-28 HK HK15106440.6A patent/HK1205932A1/xx unknown
- 2013-06-28 EP EP13822479.5A patent/EP2877179A4/en not_active Ceased
- 2013-06-28 MY MYPI2015700161A patent/MY171526A/en unknown
- 2013-06-28 HK HK15106439.9A patent/HK1205931A1/xx unknown
- 2013-06-28 JP JP2015524291A patent/JP2015522658A/ja active Pending
- 2013-06-28 RU RU2019101864A patent/RU2019101864A/ru not_active Application Discontinuation
- 2013-06-28 BR BR112015001627A patent/BR112015001627A2/pt not_active Application Discontinuation
- 2013-06-28 WO PCT/US2013/048627 patent/WO2014018223A1/en not_active Ceased
- 2013-06-28 JP JP2015524292A patent/JP2015522659A/ja active Pending
- 2013-06-28 EP EP19153805.7A patent/EP3527204A1/en not_active Withdrawn
- 2013-06-28 EP EP13823428.1A patent/EP2844241A4/en not_active Ceased
- 2013-06-28 AU AU2013293489A patent/AU2013293489B2/en not_active Ceased
- 2013-06-28 KR KR1020157005105A patent/KR20150048741A/ko not_active Ceased
- 2013-06-28 CN CN201711139409.1A patent/CN107661326A/zh active Pending
- 2013-06-28 SG SG11201500601QA patent/SG11201500601QA/en unknown
- 2013-06-28 CN CN201710662273.6A patent/CN107335057A/zh active Pending
- 2013-06-28 RU RU2015106672A patent/RU2015106672A/ru unknown
- 2013-06-28 WO PCT/US2013/048616 patent/WO2014018222A1/en not_active Ceased
- 2013-06-28 AU AU2013293488A patent/AU2013293488B2/en not_active Ceased
- 2013-06-28 CA CA2879640A patent/CA2879640A1/en not_active Abandoned
- 2013-06-28 CN CN201380037454.XA patent/CN104540505A/zh active Pending
- 2013-06-28 KR KR1020157005100A patent/KR20150048740A/ko not_active Ceased
- 2013-06-28 RU RU2015106762A patent/RU2015106762A/ru unknown
- 2013-06-28 SG SG11201500578VA patent/SG11201500578VA/en unknown
- 2013-06-28 MX MX2015001190A patent/MX2015001190A/es unknown
-
2014
- 2014-12-02 IL IL236028A patent/IL236028A0/en unknown
- 2014-12-08 ZA ZA2014/08993A patent/ZA201408993B/en unknown
-
2015
- 2015-01-11 IL IL236622A patent/IL236622A0/en not_active IP Right Cessation
- 2015-01-22 ZA ZA2015/00459A patent/ZA201500459B/en unknown
- 2015-07-06 HK HK18110004.3A patent/HK1250628A1/zh unknown
- 2015-07-06 HK HK18105893.7A patent/HK1246203A1/zh unknown
- 2015-10-02 US US14/873,919 patent/US20160022615A1/en not_active Abandoned
-
2016
- 2016-11-03 US US15/342,783 patent/US20170100351A1/en not_active Abandoned
-
2017
- 2017-10-24 JP JP2017204851A patent/JP2018039831A/ja active Pending
-
2018
- 2018-04-16 JP JP2018078173A patent/JP2018127482A/ja active Pending
- 2018-07-30 AU AU2018208765A patent/AU2018208765A1/en not_active Abandoned
- 2018-08-08 US US16/058,096 patent/US20180344674A1/en not_active Abandoned
- 2018-08-19 IL IL261232A patent/IL261232A/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2015522658A5 (enExample) | ||
| JP2012255026A5 (enExample) | ||
| JP2015510928A5 (enExample) | ||
| JP2015522659A5 (enExample) | ||
| JP2012505884A5 (enExample) | ||
| JP2015503583A5 (enExample) | ||
| JP2015078230A5 (enExample) | ||
| JP2015523407A5 (enExample) | ||
| CL2012001133A1 (es) | Composicion farmaceutica oral que comprende ponatinib 3-(imidazo[1,2-b]piridazin-3-iletinil)-4-metil-n-(4-((4-metilpiperazin-1-il)-metil)-3-(trifluorometil)fenil)benzamida y al menos un excipiente farmaceuticamente aceptable; y su uso para el tratamiento de neoplasma, cancer o un trastorno hiperproliferativo. | |
| BR112012024019A2 (pt) | forma de dosagem de liberação controlada, e, método para liberar uma droga | |
| JP2013507408A5 (enExample) | ||
| JP2013542247A5 (enExample) | ||
| CO6440564A2 (es) | Composiciones farmacéuticas de liberación inmediata que comprenden oxicodona y naloxona | |
| IL196854A (en) | Indole compounds and their appropriate pharmaceutical salts and their use in the preparation of @ drugs | |
| JP2016518337A5 (enExample) | ||
| JP2014516942A5 (enExample) | ||
| PH12013500172A1 (en) | Use of binders for manufacturing storage stable formulations | |
| JP2013231087A5 (enExample) | ||
| RU2015106672A (ru) | Фармацевтическая композиция для уменьшения частоты мочеиспускания и способ ее применения | |
| NZ714662A (en) | Extended-release formulation for reducing the frequency of urination and method of use thereof | |
| JP2012082195A5 (enExample) | ||
| JP2016530291A5 (enExample) | ||
| HRP20171742T4 (hr) | 2,4,6-trifluor-n-[6-(1-metilpiperidin-4-karbonil)piridin-2-il]benzamid, namijenjen liječenju migrene oralnom ili intravenskom primjenom | |
| JP2015516419A5 (enExample) | ||
| JP2014504636A5 (enExample) |